Current Issue
Alert me when new journal issues are available via or via
Editorial Board page i Full-Text PDF (58 KB)
Contents pages ii-iii Full-Text PDF (46 KB)
Masthead page iv Full-Text PDF (33 KB)
News and Topics
Improving urologic cancer care, 10 May 2010 Ted A. Skolarus, Sean Zhang, Brent K. Hollenbeck pages 347-349 Full Text | Full-Text PDF (127 KB)
Original Articles
Sarcoidosis and testicular cancer: A case series and literature review, 15 December 2008 Jonathan Dick, Richard H. Begent, Tim Meyer pages 350-354 Abstract | Full Text | Full-Text PDF (424 KB)
Kinetics of serum total and free prostate-specific antigen (PSA) after extended multisite prostate biopsy: Comparison among biopsy, transurethral resection of the prostate (TURP), and biopsy plus TURP, 29 December 2008 Noboru Hara, Hiroshi Koike, Tomohiro Nobushita, Norio Miyajima, Makoto Kawaguchi, Tsutomu Nishiyama, Kota Takahashi, Rudolf Hohenfellner pages 355-359 Abstract | Full Text | Full-Text PDF (309 KB)
Altered antioxidant status and lipid peroxidation in Indian patients with urothelial bladder carcinoma, 27 January 2009 Nitika Badjatia, Abhigyan Satyam, Prabhjot Singh, Amlesh Seth, Alpana Sharma pages 360-367 Abstract | Full Text | Full-Text PDF (613 KB)
Updated results of bladder-sparing trimodality approach for invasive bladder cancer, 13 April 2009 Almudena Zapatero, Carmen Martin de Vidales, Ramón Arellano, Gloria Bocardo, Mar Pérez, Patricia Ríos pages 368-374 Abstract | Full Text | Full-Text PDF (731 KB)
Seminar Section Introduction
The International Bladder Cancer Network H. Barton Grossman, Colin P.N. Dinney, Bernd J. Schmitz-Dräger, Peter J. Goebell pages 375-376 Full Text | Full-Text PDF (82 KB)
Seminar Articles
p53 immunohistochemistry in bladder cancer—a new approach to an old question Peter J. Goebell, Susan G. Groshen, Bernd J. Schmitz-Dräger, International Study-Initiative on Bladder Cancer (ISBC) pages 377-388 Abstract | Full Text | Full-Text PDF (1693 KB)
Statistical consideration for clinical biomarker research in bladder cancer Shahrokh F. Shariat, Yair Lotan, Andrew Vickers, Pierre I. Karakiewicz, Bernd J. Schmitz-Dräger, Peter J. Goebell, Nuria Malats pages 389-400 Abstract | Full Text | Full-Text PDF (1499 KB)
Molecular pathways of urothelial development and bladder tumorigenesis Mireia Castillo-Martin, Josep Domingo-Domenech, Orit Karni-Schmidt, Tulio Matos, Carlos Cordon-Cardo pages 401-408 Abstract | Full Text | Full-Text PDF (1591 KB)
Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium Peter J. Goebell, Margaret A. Knowles pages 409-428 Abstract | Full Text | Full-Text PDF (1595 KB)
Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression David J. McConkey, Sangkyou Lee, Woonyoung Choi, Mai Tran, Tadeusz Majewski, Sooyong Lee, Arlene Siefker-Radtke, Colin Dinney, Bogdan Czerniak pages 429-440 Abstract | Full Text | Full-Text PDF (2069 KB)
Considerations on implementing diagnostic markers into clinical decision making in bladder cancer Yair Lotan, Shahrokh F. Shariat, Bernd J. Schmitz-Dräger, Marta Sanchez-Carbayo, Feliksas Jankevicius, Marco Racioppi, Sarah J.P. Minner, Brigitte Stöhr, Pier Francesco Bassi, H. Barton Grossman pages 441-448 Abstract | Full Text | Full-Text PDF (273 KB)
New concepts of biobanks—strategic chance for uro-oncology Peter J. Goebell, Manuel M. Morente pages 449-457 Abstract | Full Text | Full-Text PDF (731 KB)
Survey Section Editorial Board page 458 Full-Text PDF (37 KB)
Urologic Oncology Survey
Commentary on Androgen receptor survival signaling is blocked by anti-{β}2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells: Huang WC, Zhau HE, Chung LW, Uro-Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA Kenneth S. Koeneman page 459 Full Text | Full-Text PDF (90 KB)
Commentary on Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis: Xie D, Gore C, Liu J, Pong RC, Mason R, Hao G, Long M, Kabbani W, Yu L, Zhang H, Chen H, Sun X, Boothman DA, Min W, Hsieh JT, Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX Kenneth S. Koeneman pages 459-460 Full Text | Full-Text PDF (103 KB)
Commentary on Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis: Koreckij T, Nguyen H, Brown LG, Yu EY, Vessella RL, Corey E, Department of Urology, University of Washington, Seattle, WA Kenneth S. Koeneman page 460 Full Text | Full-Text PDF (68 KB)
Commentary on Telomerase enzyme inhibition (TEI) and cytolytic therapy in the management of androgen independent osseous metastatic prostate cancer: Li Y, Malaeb BS, Li ZZ, Thompson MG, Chen Z, Corey DR, Hsieh JT, Shay JW, Koeneman KS, Department of Urologic Surgery, Center for Prostate Cancer, University of Minnesota, Minneapolis, MN Kenneth S. Koeneman pages 461-462 Full Text | Full-Text PDF (82 KB)
Commentary on The effects of telomerase inhibition on prostate tumor-initiating cells: Marian CO, Wright WE, Shay JW, Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX Kenneth S. Koeneman page 462 Full Text | Full-Text PDF (69 KB)
Commentary on Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis: Liang XJ, Meng H, Wang Y, He H, Meng J, Lu J, Wang PC, Zhao Y, Gao X, Sun B, Chen C, Xing G, Shen D, Gottesman MM, Wu Y, Yin JJ, Jia L, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China, Beijing, China Kenneth S. Koeneman pages 462-463 Full Text | Full-Text PDF (74 KB)
Information for Authors page IBC Full-Text PDF (36 KB)
Copyright © 2010 Elsevier, Inc. All rights reserved | Privacy Policy | Terms & Conditions | Feedback | About Us | Help | Contact Us | The content on this site is intended for health professionals.
